Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RAPP
Strong SellHot AirRapport Therapeutics, Inc. · Healthcare · United States · $2.3B · Avg Vol: $12M/d
COMPANY DESCRIPTION
Rapport Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for neurological disorders by leveraging its platform to selectively modulate ion channels. The company's approach aims to create highly targeted therapies that minimize off-target effects, addressing significant unmet needs in conditions like epilepsy and neuropathic pain. Its innovative platform and focus on specific ion channel pharmacology represent a strong, specialized competitive position in neuroscience drug development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | — | — | 20.0M | — | — |
| EPS | — | -23.10 | -3.78 | -2.86 | — | -3.03 | -4.09 | -5.23 | — |
| Shares | 35.4M | 35.4M | 36.6M | 47.8M | +35.0% | 48.0M | — | — | — |
| Debt | 0 | 2.1M | 1.5M | 11.5M | 131.3% | 10.1M | — | — | — |
| Equity | -10.1M | -25.6M | 305.4M | 484.7M | 58.7% | — | — | — | — |
| Op CF | — | -27.2M | -64.8M | -87.5M | — | -96.7M | — | — | — |
| Inv CF | — | -78.9M | -170.1M | -187.5M | — | — | — | — | — |
| Fin CF | — | 145.1M | 221.6M | 270.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RAPP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc.(you) | $2.3B | 19 | Strong Sell |
| BHVN | Biohaven Ltd. | $2.3B | 18 | Strong Sell |
| OCUL | Ocular Therapeutix, Inc. | $2.3B | 18 | Strong Sell |
| PVLA | Palvella Therapeutics, Inc. | $2.2B | 16 | Strong Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 20 | Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| ATAI | AtaiBeckley Inc. | $2.7B | 23 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%